Big Daddy invests in HMSR....
Sweden's Gambro Invests $9 Million in HemaSure of the U.S.
Stockholm, May 4 (Bloomberg) -- Gambro AB, the world's second-largest
provider of dialysis services, said it invested $9 million in HemaSure
Inc., a Marlborough, Massachusetts-based maker of filtration
technologies to process blood, to get access to new blood-treatment
technologies.
Gambro acquired 4.5 million shares, or 30 percent of the company, and
may buy stock for an additional $3 million between August 1999 and May
2000. Gambro will also get representation on HemaSure's boards and
committees, and COBE BCT, a U.S. unit of Gambro, has expanded its
distribution agreement with HemaSure. ''The r\LS filter system produced
by HemaSure is an excellent addition to our product offerings for our
transfusion medicine customers,'' said Ed Wood, chief executive of COBE
BCT, in a statement.
Gambro specializes in providing products and clinics for patients who
need to get their blood cleaned because they suffer from kidney disease.
Gambro currently uses a centrifugal technology, while HemaSure develops
filtration technologies.
Separately, HemaSure and COBE said they filed a lawsuit in federal court
in Denver to seek confirmation that a filter produced by HemaSure and
which will be distributed by COBE doesn't infringe patents held by East
Hills, New York-based Pall Corp., which has complained that HemaSure has
violated its patents.
Shares in Gambro rose 1.5 kronor, or 1.7 percent, to 90.5 ($10.7).
NYSE/AMEX delayed 20 min. NASDAQ delayed 15 min.
Access More Information and Services Above
©1999 Bloomberg L.P. All rights reserved. Terms of Service, Privacy
Policy and Trademarks. |
